Management of enteroperineal fistulas following pelvic exenteration: Insights from a high‐volume referral centre
Colorectal Disease · 2025
DOI: 10.1111/codi.70085 ↗Kurz gefasst
Fachartikel in der Zeitschrift Colorectal Disease, 2025. Verfasst von Darius Kang Lie Aw und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, Royal Prince Alfred Hospital, Sydney Local Health District, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Pelvic Exenteration, Postoperative Complications, Intestinal Fistula, Perineum. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Aim
Total pelvic exenteration (TPE) has emerged as the standard treatment for advanced anorectal, genitourinary and soft‐tissue pelvic tumours. Long‐term complications, particularly empty pelvis syndrome (EPS) leading to enteroperineal fistula (EPF), remain inadequately addressed. The surgical management of EPF poses significant challenges, with limited published data and no official guidelines. This study aimed to investigate the incidence and outcomes of EPFs after TPE and to describe the management of reoperative surgery in this patient cohort.
Method
Patients who underwent TPE at Royal Prince Alfred Hospital, Sydney, Australia, between 2009 and 2024 were identified. Clinical data from a prospectively maintained database on reoperative surgery for EPFs were obtained. Patients were excluded if reoperative surgery was clearly unrelated to previous exenteration. Comparisons were then made between the two strategies used for surgical management of EPFs, namely small bowel resection with anastomosis and intestinal bypass with distal limbs exclusion.
Results
Among 491 patients who underwent TPE, 22 (4.5%) developed an EPF requiring reoperative procedures. The 30‐day major complication rate was 18.2%. Postoperative complications were prevalent (95.2%) across both groups. The median time to EPF surgery post‐TPE was 21.7 months. Notably, intensive care unit (ICU) admission was 2 days shorter and length of stay was 14 days shorter in the bypass group than in the small bowel resection with anastomosis group, although both differences were not statistically significant.
Conclusion
Strategies for preventing EPFs remain elusive; however, surgical management is feasible with acceptable short‐term outcomes. The optimal strategy should be tailored to individual patient characteristics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Colorectal Surgery, Royal Prince Alfred Hospital, Sydney Local Health District, Sydney, New South Wales, Australia.
- Department of General Surgery, Seng Kang General Hospital, Singapore.
- Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, Sydney Local Health District, Sydney, New South Wales, Australia.
- Institute of Academic Surgery at RPA, Sydney, New South Wales, Australia.
- University of Sydney, Sydney, New South Wales, Australia.
ORCID-Profile: Darius Kang Lie Aw, Kilian G M Brown, Michael J Solomon
Zitieren
APA
Aw, D. K. L., Brown, K. G. M., El-Hayek, J., Cahill, M., Austin, K. K. S., Lee, P. J. M., Byrne, C., & Solomon, M. J. (2025). Management of enteroperineal fistulas following pelvic exenteration: Insights from a high‐volume referral centre. Colorectal Disease. https://doi.org/10.1111/codi.70085
Vancouver
Aw DKL, Brown KGM, El-Hayek J, Cahill M, Austin KKS, Lee PJM, et al. Management of enteroperineal fistulas following pelvic exenteration: Insights from a high‐volume referral centre. Colorectal Disease. 2025. doi:10.1111/codi.70085
BibTeX
@article{Aw2025,
author = {Aw, Darius Kang Lie and Brown, Kilian G M and El-Hayek, Jessica and Cahill, Mollie and Austin, Kirk K S and Lee, Peter Jun Myung and Byrne, Chris and Solomon, Michael J},
title = {Management of enteroperineal fistulas following pelvic exenteration: Insights from a high‐volume referral centre},
journal = {Colorectal Disease},
year = {2025},
doi = {10.1111/codi.70085}
}
EUVIMED